Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial
25/06/2026 12:23
BRIEF-Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial June 25 (Reuters) - Eledon Pharmaceuticals Inc ELDN.O:
NATERA AND ELEDON ANNOUNCE STRATEGIC PARTNERSHIP FOR PROSPERA™ MONITORING IN PLANNED PHASE 3 KIDNEY TRANSPLANT TRIAL
NATERA AND ELEDON ANNOUNCE STRATEGIC PARTNERSHIP FOR PROSPERA™ MONITORING IN PLANNED PHASE 3 KIDNEY TRANSPLANT TRIAL
NATERA - ELEDON TO INITIATE PHASE 3 KIDNEY TRANSPLANT TRIAL IN LATE 2026
Source text: ID:nBw3wq2pNa
Further company coverage: ELDN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eledon Pharmaceuticals
See all newsBrief: Eledon Presents Updated Long-Term Phase 2 Bestow Extension Study Results At The International Congress Of The Transplantation Society
Eledon Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Eledon Pharmaceuticals Q2 net loss widens on warrant liability changes
Eledon Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Natera And Eledon Announce Strategic Partnership For Prospera™ Monitoring In Planned Phase 3 Kidney Transplant Trial